Brief: Tracon Pharmaceuticals Provides Positive Update On Ongoing Envasarc Pivotal Phase 2 Trial

TRACON Pharmaceuticals

20/12/2023 13:04

Dec 20 (Reuters) - TRACON Pharmaceuticals Inc  TCON.O :
    * TRACON PHARMACEUTICALS PROVIDES POSITIVE UPDATE ON ONGOING
ENVASARC PIVOTAL PHASE 2 TRIAL
    * TRACON PHARMACEUTICALS INC - FULL ENVASARC ENROLLMENT
EXPECTED
IN 1Q 2024 AND FINAL DATA ANTICIPATED DURING 3Q 2024
    * TRACON PHARMACEUTICALS INC - OBJECTIVE RESPONSE RATE BY
INVESTIGATOR REVIEW INCREASED TO 15% SINCE INTERIM ANALYSIS IN
SEPTEMBER
    * TRACON PHARMACEUTICALS INC - UPDATED SAFETY AND EFFICACY
DATA
ARE EXPECTED IN 1Q 2024
    * TRACON PHARMACEUTICALS INC - ENVAFOLIMAB REMAINS WELL
TOLERATED
AND GRADE > 3 RELATED TOXICITY HAS NOT BEEN REPORTED TO DATE

Source text for Eikon:  ID:nGNX1ZGV3x 
Further company coverage:  TCON.O 

 ((Reuters.Briefs@thomsonreuters.com;))